Edition:
United States

MEI Pharma Inc (MEIP.OQ)

MEIP.OQ on NASDAQ Stock Exchange Capital Market

2.15USD
15 Dec 2017
Change (% chg)

$0.03 (+1.42%)
Prev Close
$2.12
Open
$2.12
Day's High
$2.24
Day's Low
$2.12
Volume
20,406
Avg. Vol
39,770
52-wk High
$3.26
52-wk Low
$1.35

Chart for

About

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company's portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the... (more)

Overall

Beta: 1.82
Market Cap(Mil.): $79.44
Shares Outstanding(Mil.): 36.95
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Mei Pharma enters into at-market equity offering sales agreement

* On Nov. 8, 2017, co entered into at--market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, as sales agent​

Nov 08 2017

BRIEF-Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib

* Mei Pharma announces exclusive license agreement with Presage Biosciences for voruciclib, an oral, selective cdk inhibitor

Sep 05 2017

BRIEF-Helsinn group and Mei Pharma announce first patient dosed in myeloid leukemia study

* Helsinn group and Mei Pharma announce first patient dosed in pivotal phase 3 study of pracinostat and azacitidine in acute myeloid leukemia Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Aug 02 2017

Earnings vs. Estimates